TOP-ART, NCT-PMO-1603 (#774)
Laufzeit: 01.01.2019 - 31.12.2040
imported
Kurzfassung
Randomized phase II study of Trabectedin/Olaparib compared to physician's choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
